Skip to main content



Local Cdiff information for Tennessee

Tennessee

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Tennessee.



Local Cdiff information for Tennessee

Tennessee

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Tennessee.

Providers

Maribeth Nicholson, MD, MPH

Associate Professor of Pediatrics Pediatric Gastroenterology, Hepatology, and Nutrition
Associate Program Director Pediatric Gastroenterology, Hepatology and Nutrition Fellowship Program

Doctors’ Office Tower
2200 Children’s Way
Room / Suite10th Floor
Nashville TN 37232-9175

Email: maribeth.r.nicholson@vumc.org

VISIT WEBSITE>

Regulation

C. diff Infections

Total Reported Cases: 1756
Hospital Onset: 1756
Community Onset: Not reported
Related Deaths: Not reported

Available Reports

Annual Progress based on SIR: 0.68
CDC STATE PROGRESS REPORT >
STATE REPORTING >

State Reporting Laws

Data Submission Required: Yes
Data Publicly Available: Yes
Data Validated: Yes
Facility-specific Data Publicly Reported: Yes
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: Yes
Law/Regulation: Not available
STATUTE >

State Contact

Marion A. Kainer MD, MPH, FRACP
Medical Epidemiologist, Infectious Diseases Physician Director
Tennessee Department of Health
Hospital Infections and Antimicrobial Resistance Program
CEDS, 1st Floor, Cordell Hull Bldg 425, 5th Avenue North
Nashville, 37243
(615) 741-7247
EMAIL MARION A. KAINER MD, MPH, FRACP >

CLINICAL TRIALS

FMT National Registry

Official Title: Fecal Microbiota Transplant National Registry
Trial No. NCT03325855
Type: Observational
Recruitment: Recruiting
Sponsor: American Gastroenterological Association
Contact: Sonya Serra, MSc
301-941-2616
EMAIL
Gender: All
Age: All ages

ROAR

Official Title: REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
Trial No. NCT05835219
Type: Observational
Recruitment: Recruiting
Sponsor: Ferring Pharmaceuticals
Contact:Global Clinical Compliance
833-548-1402
EMAIL
Gender: All
Age: 18 Years and older

RESTORATiVE303

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
EMAIL >
Gender: All
Age: 12 Years and older